Villers-lès-Nancy, 6 February 2025 - 6:00 p.m. (CET) PRESS RELEASE 2024 annual revenue: €216.8 million including €58.6 million in Q4 (+2.6% on a reported basis and -0.4% like-for-like) Revenue (€&)2023Reported basis2024Reported basisChange /Reported basisOf which external growthOf which Ségur1 2024Of which Ségur 2023Like-for-like change(organic growth)Q156.2<td style="width:75.6px;;text-align: right ; vertical-align: ...

HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE:EQS) ("Equus" or the "Fund") today announces that Fraser Atkinson has been appointed as the Fund's independent Chairman of the Board and that John J. May has been appointed as an independent director, each with immediate effect. Mr. Atkinson will continue to serve as Chair of the Equus Audit Committee, and as a member of Fund's Compensation Committee and Governance and Nominating Committee. Mr. May has been a practicing Chartered Acco ...

Acquisition Overview - Equasens Group acquires a 90% majority stake in Calimed SAS, a cloud-based medical Practice Management Software (PMS) provider, to strengthen its position in the French healthcare software market [15][1] - Calimed will become part of Equasens' Medical Solutions Division, which already serves over 25,000 users with a comprehensive range of software solutions for medical and paramedical professions [5][16] Strategic Goals - The acquisition aims to increase Equasens' market share in the French PMS market and expand its portfolio of online solutions to support the digital transition of medical practices [1] - Equasens plans to integrate Calimed's innovative modules, such as "Follow-Up" for pre-, per-, and post-operative monitoring, into its existing software range [6] - The company aims to establish easy-care as the market-leading software by leveraging synergies between Calimed and Equasens' existing solutions [21] Market Potential - The French private medical practice software market is fragmented, with significant potential for consolidation, and Equasens' Medical Solutions Division is currently the third-largest player [8] - There are 200,000 practitioners in France, including 115,000 in private practice, indicating considerable growth potential for Equasens' solutions [8] Product Innovations - Calimed's software features advanced pre-, per-, and post-operative questionnaire management and automatic data integration into Electronic Patient Records, offering time savings for surgeons [2] - Equasens plans to integrate innovative modules like the AI Loquii voice consultation assistant and PandaLab Pro inter-professional messaging system into the easy-care solution [6] - Starting in 2025, Calimed users will gain access to new digital services, such as digital prescriptions, through a gateway between Calimed and easy-care [9] Synergies and Growth - Calimed's business model is based on recurring SaaS subscription revenues, with nearly 4,000 active users and excellent customer retention rates [3] - Equasens will leverage its Private Health Cloud infrastructure, certified for hosting healthcare data, to enhance Calimed's offerings [7] - The acquisition will enable Equasens to accelerate the deployment of easy-care and recruit new clients more effectively, starting in 2025 [6] Industry Trends - The healthcare system is undergoing a digital transformation, with digital solutions emerging as a key lever for cost optimization, streamlined care pathways, and improved coordination between professionals [19] - New regulations are driving innovation and investment in open, secure, and interoperable healthcare solutions [19] Company Background - Equasens Group, founded over 35 years ago, employs over 1,300 people across Europe and is a leader in digital healthcare solutions [11] - The company's mission is to facilitate the day-to-day work of healthcare professionals through professional software, applications, and digital solutions [11]

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of September 30, 2024, of $40.2 million. Net asset value per share decreased to $2.96 as of September 30, 2024, from $3.66 as of June 30, 2024. Comparative data is summarized below (in thousands, except per share amounts):   As of the Quarter Ended9/30/20246/30/20243/31/202412/31/20239/30/2023Net assets$40,165$49,792$45,892$48,287$47,128Shares outstanding13,58613,58613,58613,58613 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 814-00098 | --- | --- | |-------------------------------------------------------------------------------------------------|--------------------- ...

HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) ("Equus" or the "Company") reports net assets as of June 30, 2024, of $49.8 million. Net asset value per share increased to $3.66 as of June 30, 2024, from $3.38 as of March 31, 2024. Comparative data is summarized below (in thousands, except per share amounts): | --- | --- | --- | --- | --- | --- | |-------------------------|-----------|-----------|------------|-----------|-----------| | | | | | | | | As of the Quarter Ended | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 814-00098 | --- | --- | |-------------------------------------------------------------------------------------------------|-------------------------- ...

HOUSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) ("Equus" or the "Company") reports net assets as of March 31, 2024, of $45.9 million. Net asset value per share decreased to $3.38 as of March 31, 2024, from $3.55 as of December 31, 2023. Comparative data is summarized below (in thousands, except per share amounts): | --- | --- | --- | --- | --- | --- | |-------------------------|-----------|------------|-----------|-----------|-----------| | | | | | | | | As of the Quarter Ende ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 814-00098 EQUUS TOTAL RETURN, INC. (Exact name of registrant as specified in its charter) Delaware 76-0345915 (State or other jurisdiction of incorp ...

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE:EQS) ("Equus" or the "Company") reports net assets as of December 31, 2023, of $48.3 million. Net asset value per share increased to $3.55 as of December 31, 2023, from $3.49 as of September 30, 2023. Comparative data is summarized below (in thousands, except per share amounts): As of the Quarter Ended12/31/20239/30/20236/30/20233/31/202312/31/2022 Net assets$48,287$47,128$40,051$34,106$35,237Shares outstanding13,58613,51813,51813,51 ...